Results 91 to 100 of about 320,397 (244)
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal+5 more
wiley +1 more source
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo+5 more
wiley +1 more source
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]
ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott+8 more
core +1 more source
Objective Cutaneous lupus erythematosus (CLE) is an inflammatory skin manifestation of systemic lupus erythematosus. Type I interferons (IFNs) promote inflammatory responses and are elevated in CLE lesions. We recently reported that CLE lesions are frequently colonized with Staphylococcus aureus.
Lisa Abernathy‐Close+9 more
wiley +1 more source
Objective Endogenous retroelements (EREs) stimulate type 1 interferon (IFN‐I) production but have not been explored as potential interferonogenic triggers in rheumatoid arthritis (RA). We investigated ERE expression in early RA (eRA), a period in which IFN‐I levels are increased.
Faye A. H. Cooles+12 more
wiley +1 more source
Objective In rheumatoid arthritis (RA) and spondyloarthritis (SpA), managing persistent pain remains challenging. Little is known regarding impaired pain pathways in these patients and the impact of biologic disease‐modifying antirheumatic drugs (bDMARDs).
Anne‐Priscille Trouvin+9 more
wiley +1 more source
Arthroscopy in Rheumatology [PDF]
Kenneth C. Kalunian, Robert W. Ike
openaire +3 more sources
Association of Synovial Innate Immune Exhaustion With Worse Pain in Knee Osteoarthritis
Objective Uncontrolled pain remains a major clinical challenge in the management of knee osteoarthritis (OA), the most common disabling joint disease. Worse pain is associated with synovial innate immune cell infiltration (synovitis), but the role of innate immune‐regulatory cells in pain is unknown. Our objective was to identify synovial innate immune
Holly T. Philpott+14 more
wiley +1 more source
Objective Little is known on the mechanisms necessary to maintain the physiologic adult human skin integrity. This study aims to quantitatively describe anatomic changes in systemic sclerosis (SSc)–skin compared with controls and investigate the underlying mechanisms.
Sara Chenguiti Fakhouri+18 more
wiley +1 more source